Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
|Articles|March 16, 2015
Partner Content: E-Mazing Medical Marketing Minute The value of before and after photos
Adam DeGraide, CEO of Crystal Clear Digital Marketing talks with John B. Lazor, M.D., M.B.A., F.A.C.S., of the New England Cosmetic Surgery and Laser Center in Weymouth, Mass. The two discuss the value of using before and after photos to educate patients on the results achievable using injectables.
Advertisement
Partner Content
Social Media for Dermatologists and Cosmetic Surgeons
Adam DeGraide, CEO of Crystal Clear Digital Marketing talks with John B. Lazor, M.D., M.B.A., F.A.C.S., of the New England Cosmetic Surgery and Laser Center in Weymouth, Mass. The two discuss the value of using before and after photos to educate patients on the results achievable using injectables.
Advertisement
Related to this article
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Advertisement
Advertisement
Trending on Dermatology Times
1
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
2
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
3
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
4
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
5